Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the tr…
$0.84+1.41%
报价 2026-11-13
市值
$290.6M
EV
$579.9M
PE (TTM)
–
预期 PE (FY2026)
–
52 周区间距高点 -72.6%
$0.83$3.06
筛选结果
pipeline · 2026-11-13Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
爆发潜力
2026-11-11不在筛选范围:industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告(约 1–3 分钟),结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
FMP 同行列表 · 2026-05-16| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| ALLOAllogene Therapeutics, Inc. | $290.6M | +1.4% | +1.3% | 0% | – | – | – | |
| AVIRAtea Pharmaceuticals, Inc. | $345.3M | +2.1% | -19.7% | 0% | – | – | – | |
| EDITEditas Medicine, Inc. | $334.9M | +1.4% | +23.2% | 56.9% | – | – | – | |
| KYTXKyverna Therapeutics, Inc. | $319.3M | +0.4% | +86.6% | 0% | – | – | – | |
| CABACabaletta Bio, Inc. | $276.1M | -3.8% | -43.2% | 0% | – | – | – | |
| VNDAVanda Pharmaceuticals Inc. | $241.3M | +1.0% | +20.3% | 93.2% | – | – | – | |
| HUMAHumacyte, Inc. | $155.1M | -6.2% | +174.1% | -533% | – | – | – | |
| VYGRVoyager Therapeutics, Inc. | $107.7M | +1.8% | +31.0% | 89.9% | – | – | – | |
| CRBUCaribou Biosciences, Inc. | $39.1M | -4.8% | +151.1% | -129.7% | – | – | – | |
| 同行中位数 | – | – | +27.1% | 0% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据(首次研究运行后填充)。